Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 21 of 45

Comparative Adverse Effects of Oral DMARDs

Oral disease-modifying anti-rheumatic drugs (DMARDs) used as monotherapies exhibit similar adverse event rates. The evidence included 3 randomized controlled trials (RCTs) with a total of 1,839 patients; 1 observational study with a total of 40,594 patients; and 3 meta-analyses with a total of 7,245 patients. The strength of evidence for this finding is moderate.

Adding a corticosteroid to treatment with oral DMARDs does not increase treatment discontinuation rates and may delay discontinuation. The evidence included 4 RCTs with a total of 1,202 patients and 1 observational study with a total of 154 patients. The strength of evidence for this finding is moderate.

Adding a corticosteroid may increase wound healing complications. The strength of evidence for this finding is low.

Oral DMARDs do not appear to elevate the risk of lymphoma. The evidence includes 2 observational studies with a total of 16,545 patients. The strength of evidence for this finding is low.